Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine + gabapentin
- Development stage
- Unknown
- Lead developer
- Tigercat Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of cyclosporine, an immunosuppressant medication used to prevent organ rejection in transplant patients and treat autoimmune conditions, and gabapentin, an anticonvulsant medication used to treat neuropathic pain, partial-onset seizures, and restless legs syndrome. The therapeutic efficacy of gabapentin may be decreased when used in combination with cyclosporine.
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)Cyp (Cyclophilin family)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on cyclosporine + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine + gabapentin.